L

Lexeo Therapeutics Inc
NASDAQ:LXEO

Watchlist Manager
Lexeo Therapeutics Inc
NASDAQ:LXEO
Watchlist
Price: 6.53 USD -0.76%
Market Cap: 215.9m USD
Have any thoughts about
Lexeo Therapeutics Inc?
Write Note

EV/FCFF
Enterprise Value to FCFF

-1.6
Current
-5.2
Median
4.1
Industry
Higher than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-1.6
=
Enterprise Value
97.4m USD
/
FCFF
-59.7m USD
All Countries
Close
Market Cap EV/FCFF
US
Lexeo Therapeutics Inc
NASDAQ:LXEO
217.6m USD -1.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -240 259.7
US
Abbvie Inc
NYSE:ABBV
315.9B USD 23.4
US
Amgen Inc
NASDAQ:AMGN
140.9B USD 29.9
US
Gilead Sciences Inc
NASDAQ:GILD
115.5B USD 11
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD -71.1
US
Epizyme Inc
F:EPE
94.1B EUR -466.9
AU
CSL Ltd
ASX:CSL
135.9B AUD 62.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD 21.5
US
Seagen Inc
F:SGT
39.3B EUR -56.3
NL
argenx SE
XBRU:ARGX
36.1B EUR -104.6
 
US
L
Lexeo Therapeutics Inc
NASDAQ:LXEO
Average EV/FCFF: 29.6
Negative Multiple: -1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -240 259.7
US
Abbvie Inc
NYSE:ABBV
23.4
US
Amgen Inc
NASDAQ:AMGN
29.9
US
Gilead Sciences Inc
NASDAQ:GILD
11
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -71.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -466.9
AU
CSL Ltd
ASX:CSL
62.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
21.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.3
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.6

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A